StreetInsider.com News Articles

Leerink Assumes Connect Biopharma Holdings Ltd (CNTB) at Outperform

Mon, 12 Oct 2026 07:19:39 -0400

Leerink analyst Will Soghikian assumes coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a Outperform rating and a price target of $4.00.

For an analyst ratings summary and ratings history on Connect Biopharma Holdings Ltd click here. For more ratings news on Connect Biopharma Holdings Ltd click here.

Shares of Connect Biopharma Holdings Ltd closed at $0.87 yesterday.

H.C. Wainwright Reiterates Buy Rating on Connect Biopharma Holdings Ltd (CNTB)

Thu, 08 Oct 2026 07:08:16 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $7.00 price target on Connect Biopharma Holdings Ltd (NASDAQ: CNTB).

The analyst commented: "When we look at the NEJM publication with Seabreeze COPD data in hand we view it as strengthening CNTB's request to the FDA to design acute asthma and COPD trials with differing primary endpoints. In asthma, rademikibart produced the expected rapid and statistically significant improvement in FEV1 by Day 7, supporting FEV1 as a logical Phase 3 endpoint. In COPD, however, the most compelling rademikibart effects were an 81% reduction in treatment failure, 85% reduction in new moderate/severe

Form SCHEDULE 13G Connect Biopharma Holdin Filed by: BML Investment Partners, L.P.

Tue, 06 Oct 2026 19:53:00 -0400

si-local-file:///var/storage/secattach/20261006/27156625.html

Form 4 Connect Biopharma Holdin For: Sep 30 Filed by: Xanthopoulos Kleanthis Gabriel

Thu, 01 Oct 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20261001/27137232.html

Form 4 Connect Biopharma Holdin For: Sep 30 Filed by: LIU JEAN I

Thu, 01 Oct 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20261001/27137210.html

Connect Biopharma Holdings Ltd (CNTB) PT Lowered to $5 at BTIG

Wed, 30 Sep 2026 12:38:43 -0400

BTIG analyst Julian Harrison lowered the price target on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) to $5.00 (from $10.00) while maintaining a Buy rating.

The analyst comments "CNTB shared Seabreeze STAT COPD met its primary endpoint of reduction in treatment failure rate (81% reduction vs. pbo, p=0.0122), with 0 patients in the rademikibart treatment arm returning to the hospital or emergency department (ED; vs. 8.6% of pbo-treated patients, p=0.0137). Acute COPD has high unmet need and expensive consequences from suboptimal care, and these initial results highlight how rademikibart could reduce hospital utilization, making a strong case to payors for use. CNTB

Connect Biopharma Holdings Ltd (CNTB) PT Lowered to $5 at BTIG

Wed, 30 Sep 2026 12:38:43 -0400

BTIG analyst Julian Harrison lowered the price target on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) to $5.00 (from $10.00) while maintaining a Buy rating.

Connect Biopharma stock jumps on positive COPD trial data

Wed, 30 Sep 2026 10:46:43 -0400

Investing.com -- Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB) shares jumped 25% Wednesday after the company reported positive Phase 2 trial results for rademikibart, its drug candidate for treating acute exacerbations in chronic obstructive pulmonary disease patients.

The Seabreeze STAT COPD study showed rademikibart significantly reduced the rate of treatment failure by 81% through one month compared to placebo. The drug also reduced new moderate to severe COPD exacerbations by 85% and eliminated hospitalizations or emergency department visits for new acute COPD exacerbations by 100% during the same period.

The Phase 2 study enrolled 159 participants globally with an eosinophil count of at

Connect Biopharma stock jumps on positive COPD trial data

Wed, 30 Sep 2026 10:46:43 -0400

The Phase 2 study enrolled 159 participants globally with an eosinophil count of at

3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours